Journal of Acquired Immune Deficiency Syndromes

Journal

Publication Venue For

  • The Impact of Cumulative Depression Along the HIV Care Continuum in Women Living With HIV During the Era of Universal Antiretroviral Treatment.  82:225-233. 2019
  • Internalized HIV Stigma Is Associated With Concurrent Viremia and Poor Retention in a Cohort of US Patients in HIV Care.  82:116-123. 2019
  • Brief Report: Aging Attenuates the Association Between Coronary Artery Calcification and Bone Loss Among HIV-Infected Persons.  82:46-50. 2019
  • Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART.  81. 2019
  • Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV..  79:283-287. 2018
  • Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.  78:202-208. 2018
  • Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes.  77:257-263. 2018
  • Reply.  77:e22. 2018
  • Reply..  77:e22. 2018
  • HIV Continuum of Care for Youth in the United States.  77:110-117. 2018
  • Partner Notification for Youth Living With HIV in 14 Cities in the United States.  77:46-52. 2018
  • Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058..  68:554-561. 2015
  • Biomarkers to monitor safety in people on art and risk of mortality..  60:51-58. 2012
  • Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination..  61:390-399. 2012
  • A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.  56. 2011
  • Systemic and mucosal differences in hiv burden, immune, and therapeutic responses.  56:401-411. 2011
  • Hepatitis B vaccination in HIV-infected youth: A randomized trial of three regimens.  56:325-332. 2011
  • The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.  56:340-343. 2011
  • CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.  56:213-221. 2011
  • Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: Still a missed opportunity for public health and HIV prevention.  55. 2010
  • Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the roche COBAS ampliprep/COBAS TaqMan HIV-1 Version 1.0 viral load test.  54:442-444. 2010
  • Epidemiology of HIV infection and risk in adolescents and youth.  54. 2010
  • Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.  54:63-70. 2010
  • Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.  53:215-221. 2010
  • Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent haart Era.  53:102-106. 2010
  • Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.  52:357-363. 2009
  • Gender differences in discontinuation of antiretroviral treatment regimens.  52:336-341. 2009
  • Predictors of rapid HIV testing acceptance and successful nevirapine administration in zambian labor wards.  52:273-279. 2009
  • The major histocompatibility complex conserved extended haplotype 8.1 in aids-related non-hodgkin lymphoma.  52:170-179. 2009
  • Effect of flash-heat treatment on immunoglobulins in breast milk.  51:264-267. 2009
  • Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.  50:290-293. 2009
  • Racial disparities in HIV virologic failure: Do missed visits matter?.  50:100-108. 2009
  • Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study.  48:142-148. 2008
  • Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women.  48:203-210. 2008
  • Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals.  48:169-176. 2008
  • Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: A case series and systematic review.  48:63-67. 2008
  • Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.  47:553-558. 2008
  • Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186.  47:459-466. 2008
  • The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy.  47:194-201. 2008
  • Enrollment and retention of HIV discordant couples in Lusaka, Zambia.  47:116-125. 2008
  • Inclusion of adolescents in preventive HIV vaccine trials: Public health policy and research design at a crossroads.  47:86-92. 2008
  • Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients.  46:607-615. 2007
  • Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women.  45:60-65. 2007
  • Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings.  44:525-530. 2007
  • Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum..  43:378-380. 2006
  • Multiperson use of syringes among injection drug users in a needle exchange program: A gene-based molecular epidemiologic analysis.  43:335-343. 2006
  • Bacterial disease in HIV-infected patients: The blind spot of highly active antiretroviral therapy? [3].  41:532-535. 2006
  • Risk for HIV-1 infection associated with a common CXCL12 (SDF1) polymorphism and CXCR4 variation in an African population.  40:521-526. 2005
  • Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.  40:301-306. 2005
  • Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance.  39:272-283. 2005
  • Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents.  38:180-190. 2005
  • Association of complementary and alternative medicines with HIV clinical disease among a cohort of women living with HIV/AIDS.  37:1415-1422. 2004
  • Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.  37:1358-1366. 2004
  • Cytokine and Chemokine Gene Polymorphisms among Ethnically Diverse North Americans with HIV-1 Infection.  35:446-454. 2004
  • Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients.  35:239-252. 2004
  • Detection of Nevirapine in Plasma Using Thin-Layer Chromatography.  35:155-157. 2004
  • Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025.  35:138-143. 2004
  • A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program..  37 Suppl 2. 2004
  • Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.  33:426-438. 2003
  • Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1.  33:343-348. 2003
  • The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-1-seropositive whites.  33:140-145. 2003
  • Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection.  33:56-65. 2003
  • Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.  32:506-513. 2003
  • Voluntary Counseling and Testing for HIV Among Pregnant Women Presenting in Labor in Kigali, Rwanda.  31:408-415. 2002
  • Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel.  31:257-275. 2002
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A.  29:254-261. 2002
  • Pharmacokinetic enhancement of protease inhibitors.  29. 2002
  • International Standard Serial Number (issn)

  • 1525-4135
  • Electronic International Standard Serial Number (eissn)

  • 1944-7884